OCS
Price:
$19.7
Market Cap:
$828.33M
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Industry
Biotechnology
IPO Date
2021-05-18
Stock Exchange
NASDAQ
Ticker
OCS
According to Oculis Holding AG’s latest financial reports and current stock price. The company's current PE Ratio is -7.32. This represents a change of 16.95% compared to the average of -6.26 of the last 4 quarters.
The mean historical PE Ratio of Oculis Holding AG over the last ten years is -10.57. The current -7.32 PE Ratio has changed 6.83% with respect to the historical average. Over the past ten years (40 quarters), OCS's PE Ratio was at its highest in in the March 2023 quarter at -1.22. The PE Ratio was at its lowest in in the September 2021 quarter at -14.81.
Average
-10.57
Median
-7.90
Minimum
-18.91
Maximum
-3.18
Discovering the peaks and valleys of Oculis Holding AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 128.67%
Maximum Annual PE Ratio = -3.18
Minimum Annual Increase = -59.73%
Minimum Annual PE Ratio = -18.91
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -7.27 | 128.67% |
| 2023 | -3.18 | -59.73% |
| 2022 | -7.90 | -49.35% |
| 2021 | -15.59 | -17.55% |
The current PE Ratio of Oculis Holding AG (OCS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.11
5-year avg
-10.57
10-year avg
-10.57
Oculis Holding AG’s PE Ratio is greater than Xencor, Inc. (-7.58), greater than Kodiak Sciences Inc. (-8.40), greater than AnaptysBio, Inc. (-14.24), greater than UroGen Pharma Ltd. (-7.48), less than Phathom Pharmaceuticals, Inc. (-3.93), less than Nurix Therapeutics, Inc. (-6.20), greater than Nektar Therapeutics (-9.05), less than Sana Biotechnology, Inc. (-4.90), less than BridgeBio Oncology Therapeutics Inc. (-2.36), less than Mind Medicine (MindMed) Inc. (-6.35),
| Company | PE Ratio | Market cap |
|---|---|---|
| -7.58 | $1.30B | |
| -8.40 | $1.31B | |
| -14.24 | $1.20B | |
| -7.48 | $1.14B | |
| -3.93 | $1.05B | |
| -6.20 | $1.39B | |
| -9.05 | $1.17B | |
| -4.90 | $1.38B | |
| -2.36 | $923.07M | |
| -6.35 | $939.13M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oculis Holding AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oculis Holding AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oculis Holding AG's PE Ratio?
How is the PE Ratio calculated for Oculis Holding AG (OCS)?
What is the highest PE Ratio for Oculis Holding AG (OCS)?
What is the 3-year average PE Ratio for Oculis Holding AG (OCS)?
What is the 5-year average PE Ratio for Oculis Holding AG (OCS)?
How does the current PE Ratio for Oculis Holding AG (OCS) compare to its historical average?